Why is Pfizer falling/rising?

As of 23-Sep, Pfizer Ltd. is experiencing a decline in its stock price, currently at 5,012.00, reflecting a decrease of 57.15 points or 1.13%. The stock has underperformed its sector by 0.78% today and has been on a consecutive four-day losing streak, resulting in a total decline of 3.65% during this period. Over the past week, the stock has decreased by 2.82%, and it has shown a significant drop of 11.51% over the last month, while year-to-date performance is down by 4.61%. Despite these declines, the company maintains a high management efficiency with a return on equity (ROE) of 18.22% and a low debt-to-equity ratio, which could indicate stability. Additionally, the stock offers a high dividend yield of 3.25%, which may attract some investors despite the recent price drop.
In the broader market context, Pfizer's recent performance contrasts sharply with the Sensex, which has seen a slight increase of 0.98% over the past month. The stock's underperformance relative to the benchmark is evident, particularly in the short term, where it has lost more than eight times the percentage decline of the Sensex over the same period. This disparity highlights investor sentiment that may be cautious regarding Pfizer's near-term outlook, despite positive operational cash flow results and strong dividend payouts. The rising delivery volume indicates increased investor participation, but the overall trend suggests that market conditions are currently unfavorable for Pfizer.